NovoSeven (Novo Nordisk)
NovoSeven (Novo Nordisk) - General Information
Recombinant human coagulation Factor VIIa (rFVIIa), intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade.1 NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues. Cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.
Pharmacology of NovoSeven (Novo Nordisk)
Used in the treatment of bleeding episodes in hemophilia A or B. NovoSeven is recombinant Factor VIIa and, when complexed with tissue factor can activate coagulation Factor X to Factor Xa, as well as coagulation Factor IX to Factor IXa. Factor Xa, in complex with other factors, then converts prothrombin to thrombin, which leads to the formation of a hemostatic plug by converting fibrinogen to fibrin and thereby inducing local clotting.
NovoSeven (Novo Nordisk) for patients
NovoSeven (Novo Nordisk) Interactions
The risk of a potential interaction between NovoSeven and coagulation factor concentrates has not been adequately evaluated in preclinical or clinical studies. Simultaneous use of activated prothrombin complex concentrates or prothrombin complex concentrates should be avoided.
Although the specific drug interaction was not studied in a clinical trial, there have been more than 50 episodes of concomitant use of antifibrinolytic therapies (i.e., tranexamic acid, aminocaproic acid) and NovoSeven.
NovoSeven should not be mixed with infusion solutions until clinical data are available to direct this use.
NovoSeven (Novo Nordisk) Contraindications
NovoSeven Coagulation Factor VIIa (Recombinant) should not be administered to patients with known hypersensitivity to NovoSeven or any of the components of NovoSeven. NovoSeven is contraindicated in patients with known hypersensitivity to mouse, hamster, or bovine proteins.
Additional information about NovoSeven (Novo Nordisk)
NovoSeven (Novo Nordisk) Indication: For treatment of hemorrhagic complications in hemophilia A and B
Mechanism Of Action: NovoSeven activates the coagulation or clotting cascade by cleaving Factor IX and Factor X, which activates them and then leads to activation of thrombin and fibrin.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Coagulation factor VIIa
Synonyms: Coagulation factor VII precursor; Eptacog alfa; Proconvertin; SPCA; Serum prothrombin conversion accelerator
Drug Category: Coagulants; Thrombotic Agents
Drug Type: Biotech; Approved
Other Brand Names containing Coagulation factor VIIa: NovoSeven (Novo Nordisk);
Absorption: Not Available
Toxicity (Overdose): Not Available
Protein Binding: Not Available
Biotransformation: Not Available
Half Life: Not Available
Dosage Forms of NovoSeven (Novo Nordisk): Injection, powder, lyophilized, for solution Intravenous bolus
Chemical IUPAC Name: Human coagulation factor VIIa
Chemical Formula: C1972H3076N560O597S28
Coagulation factor VIIa on Wikipedia: https://en.wikipedia.org/wiki/Factor_VII
Organisms Affected: Humans and other mammals
